Evidence map›Paper›PMID 26242599›Full record

ArticleMucosal immunology2016

The function and affinity maturation of HIV-1 gp120-specific monoclonal antibodies derived from colostral B cells.

T L Jeffries, C R Sacha, J Pollara, J Himes, F H Jaeger, S M Dennison, E McGuire, E Kunz, J A Eudailey, A M Trama and 10 more

Open access · bronzeAbstract read
In one paragraph

Article in Mucosal immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 1 country.

T L JeffriesDuke University Medical Center, Duke Human Vaccine Institute, Durham, North Carolina, USA.
C R SachaDuke University Medical Center, Duke Human Vaccine Institute, Durham, North Carolina, USA.
J PollaraDuke University Medical Center, Duke Human Vaccine Institute, Durham, North Carolina, USA.
J HimesDuke University Medical Center, Duke Human Vaccine Institute, Durham, North Carolina, USA.
F H JaegerDuke University Medical Center, Duke Human Vaccine Institute, Durham, North Carolina, USA.
S M DennisonDuke University Medical Center, Duke Human Vaccine Institute, Durham, North Carolina, USA.
E McGuireDuke University Medical Center, Duke Human Vaccine Institute, Durham, North Carolina, USA.
E KunzDuke University Medical Center, Duke Human Vaccine Institute, Durham, North Carolina, USA.
J A EudaileyDuke University Medical Center, Duke Human Vaccine Institute, Durham, North Carolina, USA.
A M TramaDuke University Medical Center, Duke Human Vaccine Institute, Durham, North Carolina, USA.
C LaBrancheDuke University Medical Center, Duke Human Vaccine Institute, Durham, North Carolina, USA.
G G FoudaDuke University Medical Center, Duke Human Vaccine Institute, Durham, North Carolina, USA.
K WieheDuke University Medical Center, Duke Human Vaccine Institute, Durham, North Carolina, USA.
D C MontefioriDuke University Medical Center, Duke Human Vaccine Institute, Durham, North Carolina, USA.
B F HaynesDuke University Medical Center, Duke Human Vaccine Institute, Durham, North Carolina, USA.
H-X LiaoDuke University Medical Center, Duke Human Vaccine Institute, Durham, North Carolina, USA.
G FerrariDepartment of Surgery, Duke University, Durham, North Carolina, USA.
S M AlamDuke University Medical Center, Duke Human Vaccine Institute, Durham, North Carolina, USA.
M A MoodyDuke University Medical Center, Duke Human Vaccine Institute, Durham, North Carolina, USA.
S R PermarDepartment of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA.
Duke Medical Center · USDuke University · US

Funding

Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI HAHN, BEATRICE H · 2012 to 2018
$204.7M
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
Transmission-blocking potential of novel HIV Env-specific mucosal antibodiesR01AI106380 · NIAID · DUKE UNIVERSITY · PI PERMAR, SALLIE R. · 2013 to 2017
$3.4M
NIAID NIH HHS R01 AI106380NIAID NIH HHS UM1 AI100645NIAID NIH HHS UM1-AI100645-01PHS HHS 5P30 A1064518
6 · The paper itself

Abstract

Despite the risk of transmitting HIV-1, mothers in resource-poor areas are encouraged to breastfeed their infants because of beneficial immunologic and nutritional factors in milk. Interestingly, in the absence of antiretroviral prophylaxis, the overwhelming majority of HIV-1-exposed, breastfeeding infants are naturally protected from infection. To understand the role of HIV-1 envelope (Env)-specific antibodies in breast milk in natural protection against infant virus transmission, we produced 19 HIV-1 Env-specific monoclonal antibodies (mAbs) isolated from colostrum B cells of HIV-1-infected mothers and investigated their specificity, evolution, and anti-HIV-1 functions. Despite the previously reported genetic compartmentalization and gp120-specific bias of colostrum HIV Env-specific B cells, the colostrum Env-specific mAbs described here demonstrated a broad range of gp120 epitope specificities and functions, including inhibition of epithelial cell binding and dendritic cell-mediated virus transfer, neutralization, and antibody-dependent cellular cytotoxicity. We also identified divergent patterns of colostrum Env-specific B-cell lineage evolution with respect to crossreactivity to gastrointestinal commensal bacteria, indicating that commensal bacterial antigens play a role in shaping the local breast milk immunoglobulin G (IgG) repertoire. Maternal vaccine strategies to specifically target this breast milk B-cell population may be necessary to achieve safe breastfeeding for all HIV-1-exposed infants.

Indexed as

Antibodies, MonoclonalAntibodies, NeutralizingAntibody AffinityAntibody SpecificityB-LymphocytesBreast FeedingColostrumCross ReactionsDendritic CellsDisease ResistanceEpithelial CellsFemaleGastrointestinal MicrobiomeHIV-1HIV AntibodiesHIV Envelope Protein gp120Antibodies, MonoclonalAntibodies, NeutralizingHIV AntibodiesHIV Envelope Protein gp120Immunoglobulin G

Identifiers

PMID26242599
PMCPMC4744153
OpenAlexW1077878401

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.